HIGHLIGHTS
- who: Zhou Zhu from the Published in partnership with The Hormel Institute, University of Minnesota have published the paper: Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib, in the Journal: (JOURNAL) of 28/09/2021
- what: To gain further insights into the clinical benefit from adding CDK4/6 inhibitors to ET, which is becoming the standard of care in HR+ advanced or metastatic breast cancer, here the authors compare the gene_expression/PFS relationship from the two trials in a systematic manner. Together with the observation that palbociclib can modulate estrogen receptors even on . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.